Efficacy and safety of pemafibrate versus bezafibrate in coronary artery disease patients receiving statin treatment: a randomized, open-label, cross-over study

27 August 2022 (14:15 - 15:00)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Doctor Akihiro Nakamura

Iwate Prefectural Central Hospital, Morioka (Japan)

5 More presentations in this session

Presentation thumbnail

LDL levels and long-term all-cause mortality in patients from nationwide LIPIDOGRAM 2004-2015 cohort studies.

Professor M. Banach (Lodz, PL)

Abstract Slides

Presentation thumbnail

Preliminary results from REALITY: a nation-wide study of a database with 1.8 million real-life patients to study atherosclerotic cardiovascular disease and familial hypercholesterolemia in Spain

Professor V. Barrios (Madrid, ES)

Abstract Slides

Presentation thumbnail

Statin therapy in children with familial hypercholesterolemia: A meta-analysis.

Doctor J. Lewek (Lodz, PL)

Abstract Slides

Presentation thumbnail

Low-density lipoprotein cholesterol target attainment among statin-naive Chinese atherosclerotic vascular disease patients

Ms H. Sun (Shatin, HK)

Abstract Slides

Presentation thumbnail

High long-term persistence to evolocumab treatment regimens in European clinical practice: analysis of the HEYMANS registry

Doctor M. Sibartie (Uxbridge, GB)

Abstract Slides

Access the full session

Session thumbnail

Current issues in lipid-lowering therapy

The Event

Event poster

ESC Congress 2022

27 August 2022 14:15 CET

You may be interested in

Congress Presentation

Where are we now? Decision-making in LDL-C lowering and CV risk

Webinar

Unmet needs in lipid management: treatment goals and how to achieve them

Congress Presentation

2025 Focused Update of the 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources